Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Abstract P1-05-30: A statistical model for integration of on-treatment circulating tumor DNA dynamics and prediction of outcomes in patients with ER+/HER2- metastatic breast cancer

Mitchell Elliott, Jesús Fuentes-Antrás, Sasha Main, Aaron Dou, Elizabeth Shah, Emily Van de Laar, Caroline M. Weipert, Amar Das, Eitan Amir, Michelle B. Nadler, Celeste Yu, Hal K. Berman, Lillian L. Siu, Philippe L. Bedard, David W. Cescon, Christopher Pretz

Clin Cancer Res (2025) 31 (12_Supplement): P1-05-30.

https://doi.org/10.1158/1557-3265.SABCS24-P1-05-30

Published: 13 June 2025

View articletitled, Abstract P1-05-30: A statistical model for integration of on-treatment circulating tumor DNA dynamics and prediction of outcomes in patients with ER+/HER2- metastatic breast cancer

Journal Articles

Abstract PS9-05: Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer

Clin Cancer Res (2025) 31 (12_Supplement): PS9-05.

https://doi.org/10.1158/1557-3265.SABCS24-PS9-05

Published: 13 June 2025

View articletitled, Abstract PS9-05: Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer

Journal Articles

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Clin Cancer Res (2025) 31 (11): 2134–2144.

https://doi.org/10.1158/1078-0432.CCR-24-0439

Published: 03 June 2025

View articletitled, Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Includes: Supplementary data

Journal Articles

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Licitra, Kevin Harrington, Robert Haddad, Lillian L. Siu, Yi-Chun Liu, Makoto Tahara, Jean-Pascal Machiels, Danny Rischin, Tanguy Y. Seiwert, Robert L. Ferris, Ulrich Keilholz, Amanda Psyrri, Bhumsuk Keam, Paolo Bossi, Robert Metcalf, Ching-Yun Hsieh, Paul M.J. Clement, Pavel Isaev, Ali Mudunov, José Dinis, Ann Hoeben, Stefan Kasper, Konrad Klinghammer, Michael Hwang, Jorge Blando, Olivier Serrano, Dario Ruscica, Roger B. Cohen, for the INTERLINK-1 investigators, Douglas R. Adkins, Lucia Aguas, Myung Ju Ahn, Yolanda Escobar Álvarez, Jessica R. Bauman, Maureen Bernadach, Federica Bertolini, Marcelo R. Bonomi, Christian Borel, Paolo Bossi, Michael Boyer, Santiago Cabezas Camarero, Tsung-Ming Chen, Wonyoung Choi, Vyacheslav Chubenko, Paul Clement, Roger B. Cohen, Anirudha Dasgupta, Amaury Daste, Helena Rodrigues de Andrade, Jan Paul de Boer, Thiago Bueno de Oliveira, Charles AJ de Padua, Jan H. Demol, Joao Dias, Andreas Dietz, José Dinis, Lara Carmen Iglesias Docampo, Lucas Vieira dos Santos, Khashayar Esfahani, Agustin Horacio Falco, Jérôme Fayette, Chistian Sebastian Fuentes, Madoka Furukawa, Danilo Galizia, Hui K. Gan, Irene Braña García, Maria Ghi, Robert I. Haddad, Simon Häfliger, Kevin Harrington, Stephanie Henry, Ann Hoeben, Yoshitaka Honma, Ching-Yun Hsieh, Pavel A. Isaev, Philipp Ivanyi, Demetria I. Jacks, Alfonso Berrocal Jaime, Michael J. Jelinek, Ana Joaquim, Ricklie Julian, Michalis Karamouzis, Stefan Kasper, Bhumsuk Keam, Charles Kelly, Sung-Bae Kim, Ji-Won Kim, Hee Kyung Kim, Naomi Kiyota, Konrad Klinghammer, Svetlana Kutukova, Simon A. Laban, Rubi K. Li, Lisa F. Licitra, Jin-Ching Lin, Yi-Chun Liu, Lorenzo Livi, Silvia Lopes, Jean-Pascal Machiels, Milena Mak, Muneyuki Masuda, Thibault Mazard, Robert L. Metcalf, Brandon M. Meyers, Aurora Mirabile, Ali Mudunov, Urs Müller-Richter, Prakash C. Neupane, Grzegorz S. Obara, Obiageli U. Ogbata, Kenji Okami, Nobuhiko Oridate, Konstantinos Papazizis, Martín Paskevicius, Dainik Patel, Konstantin Penkov, Francesco Perri, Petar Petrov, Zia Poonja, Marshall R. Posner, Rafaela Pozzobon, Katharine A. Price, Amanda Psyrri, John Querol, Justyna K. Rawluk, Danny Rischin, Sacha Rothschild, Paweł Różanowski, Rossitza Krasteva Ruseva, Sebastien Salas, Seong-Hoon Shin, Hitesh B. Singh, Lillian L. Siu, Martin Smoragiewicz, Paul L. Swiecicki, Petr Szturz, Masahiro Tabata, Makoto Tahara, Shunji Takahashi, Kaoru Tanaka, Margarida Teixeira, Clémence Toullec, Petranka P. Troyanova, Tsutomu Ueda, Charles Uy, Carla M. van Herpen, Marek Wojtukiewicz, Muh-Hwa Yang, Cheng T. Yen, Chia-Jui Yen, Tomoya Yokota, Dan P. Zandberg, Sylvie Zanetta, Bogdan A. Żurawski

Clin Cancer Res OF1–OF11.

https://doi.org/10.1158/1078-0432.CCR-25-0073

Published: 21 May 2025

View articletitled, INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes

Patricia McCoon, Ying Wang, Zhongwu Lai, Qu Zhang, Weimin Li, Sophie Wildsmith, Nassim Morsli, Rajiv Raja, Nicholas Holoweckyj, Jill Walker, Melissa de los Reyes, Ricard Mesía, Lisa Licitra, Robert L. Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Robert Haddad

Clin Cancer Res (2025) 31 (10): 1931–1942.

https://doi.org/10.1158/1078-0432.CCR-24-2198

Published: 15 May 2025

View articletitled, Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes

Includes: Supplementary data

Journal Articles

AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors

Clin Cancer Res (2025) 31 (8): 1449–1462.

https://doi.org/10.1158/1078-0432.CCR-24-1818

Published: 14 April 2025

View articletitled, AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer

Clin Cancer Res (2025) 31 (8): 1520–1532.

https://doi.org/10.1158/1078-0432.CCR-24-3472

Published: 14 April 2025

View articletitled, Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer

Includes: Supplementary data

Journal Articles

Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Clin Cancer Res (2023) 29 (20): 4128–4138.

https://doi.org/10.1158/1078-0432.CCR-23-1137

Published: 13 October 2023

View articletitled, Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Includes: Supplementary data

Journal Articles

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clin Cancer Res (2023) 29 (11): 2066–2074.

https://doi.org/10.1158/1078-0432.CCR-22-2765

Published: 01 June 2023

View articletitled, Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Clin Cancer Res (2023) 29 (10): 1869–1878.

https://doi.org/10.1158/1078-0432.CCR-22-2955

Published: 15 May 2023

View articletitled, Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Includes: Supplementary data

Journal Articles

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

Clin Cancer Res (2022) 28 (21): 4593–4599.

https://doi.org/10.1158/1078-0432.CCR-22-3167

Published: 01 November 2022

View articletitled, The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Journal Articles

Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror

Clin Cancer Res (2022) 28 (18): 4158.

https://doi.org/10.1158/1078-0432.CCR-22-2320

Published: 15 September 2022

View articletitled, Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Journal Articles

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Clin Cancer Res (2022) 28 (16): 3452–3463.

https://doi.org/10.1158/1078-0432.CCR-21-4020

Published: 15 August 2022

View articletitled, First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Clin Cancer Res (2022) 28 (11): 2257–2269.

https://doi.org/10.1158/1078-0432.CCR-21-3087

Published: 01 June 2022

View articletitled, A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Clin Cancer Res (2022) 28 (8): 1734.

https://doi.org/10.1158/1078-0432.CCR-22-0564

Published: 14 April 2022

View articletitled, Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Journal Articles

First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Clin Cancer Res (2022) 28 (1): 57–70.

https://doi.org/10.1158/1078-0432.CCR-21-2160

Published: 01 January 2022

View articletitled, First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA

Eric Leung, Kathy Han, Jinfeng Zou, Zhen Zhao, Yangqiao Zheng, Ting Ting Wang, Ariana Rostami, Lillian L. Siu, Trevor J. Pugh, Scott V. Bratman

Clin Cancer Res (2021) 27 (21): 5857–5868.

https://doi.org/10.1158/1078-0432.CCR-19-2384

Published: 01 November 2021

View articletitled, HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA

Includes: Supplementary data

Journal Articles

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Justin M. Burgener, Jinfeng Zou, Zhen Zhao, Yangqiao Zheng, Shu Yi Shen, Shao Hui Huang, Sareh Keshavarzi, Wei Xu, Fei-Fei Liu, Geoffrey Liu, John N. Waldron, Ilan Weinreb, Anna Spreafico, Lillian L. Siu, John R. de Almeida, David P. Goldstein, Michael M. Hoffman, Daniel D. De Carvalho, Scott V. Bratman

Clin Cancer Res (2021) 27 (15): 4230–4244.

https://doi.org/10.1158/1078-0432.CCR-21-0110

Published: 01 August 2021

View articletitled, Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Clin Cancer Res (2020) 26 (20): 5329–5337.

https://doi.org/10.1158/1078-0432.CCR-20-1412

Published: 15 October 2020

View articletitled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Journal Articles

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo Fernandez, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Jonathan Cheng, Wendy Snyder, Lillian L. Siu

Clin Cancer Res (2020) 26 (19): 5153–5161.

https://doi.org/10.1158/1078-0432.CCR-20-1170

Published: 01 October 2020

View articletitled, Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P1-05-30: A statistical model for integration of on-treatment circulating tumor DNA dynamics and prediction of outcomes in patients with ER+/HER2- metastatic breast cancer

Abstract PS9-05: Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes

AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors

Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer

Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only